沙格列汀联合胰岛素用药在2型糖尿病治疗中的作用探究(1)
[摘要] 目的 探究沙格列汀联合胰岛素用药在2型糖尿病治疗中的作用。 方法 将2017年1月—2018年5月在该院治疗的2型糖尿病患者92例作为研究对象，根据临床前瞻性研究原则，采用掷币随机法，将之分为两组，各46例，对照组给予胰岛素皮下注射治疗，观察组给予沙格列汀联合胰岛素治疗，对比两组治疗效果。 结果 治疗前，两组FPG、2 hPG、HbAlc差异无统计学意义(P>0.05);治疗后，两组FPG、2 hPG、HbAlc显著降低，且观察组低于对照组，两组数据差异有统计学意义(P<0.05)。 结论2型糖尿病治疗中联用沙格列汀、胰岛素，疗效显著，值得在临床实践中推广及使用。
[关键词] 沙格列汀;胰岛素;2型糖尿病;治疗;作用
[中图分类号] R9 [文献标识码] A [文章编号] 1672-4062(2019)02(b)-0082-02
The Role of Saxagliptin Combined with Insulin in the Treatment of Type 2 Diabetes
HU Kai-yan
Zhutian Town Health Center， Feixian County， Linyi， Shandong Province， 273400 China
[Abstract] Objective To investigate the role of saxagliptin in combination with insulin in the treatment of type 2 diabetes. Methods A total of 92 patients with type 2 diabetes mellitus who were treated in our hospital from January 2017 to May 2018 were enrolled in the study. According to the principle of clinical prospective research， the randomized method by using coins was used to divide the disease into two groups， 46 cases each. The control group was given subcutaneous injection of insulin， and the observation group was given saxagliptin combined with insulin treatment， and the therapeutic effects of the two groups were compared. Results There was no significant difference in FPG， 2 hPG and HbAlc between the two groups before treatment (P>0.05). After treatment， the FPG， 2 hPG and HbAlc were significantly lower in the two groups， and the observation group was lower than the control group. The difference between the two groups was significant (P<0.05). Conclusion The combination of saxagliptin and insulin in the treatment of type 2 diabetes is effective and worthy of promotion and use in clinical practice.
[Key words] Saxagliptin; Insulin; Type 2 diabetes; Treatment; Role
糖尿病是一種临床常见的代谢性疾病，其基本特征为高血糖，根据病症特点，可分为I型糖尿病和2型糖尿病这两种症型，其中90.0%患者都属于2型糖尿病，由胰岛素生物作用受损致病，在临床上表现为过度肥胖、疲乏无力等症状[1-2]。作为一种慢性进展性疾病，糖尿病会使得患者长期血糖偏高，并发酮症酸中毒、高渗性高血糖状态、心脑血管疾病、糖尿病肾病、糖尿病周围神经病变等症状，导致患者残疾甚至危及患者性命，必须及时予以治疗。此次试验在2型糖尿病治疗中应用了沙格列汀联合胰岛素用药方案，反响甚好，现报道如下。
1 资料与方法
1.1 一般资料
将在该院治疗的2型糖尿病患者92例作为研究对象，根据临床前瞻性研究原则，采用掷币随机法，将之分为两组，各46例。患者基本资料为：①对照组。男性26例，女性20例，年龄最小者45岁，最大者76岁，平均年龄为(60.15±4.28)岁;病程最短为10个月，最长为9年，平均病程为(4.81±1.26)年;②观察组。男性27例，女性19例，年龄最小者46岁，最大者77岁，平均年龄为(60.53±4.12)岁;病程最短为11个月，最长为9年，平均病程为(4.75±1.30)年。从性别及年龄分布、病程等基本资料上看，对照组和观察组差异无统计学意义(P>0.05)，可进行对比研究。, http://www.100md.com(胡开艳)
[关键词] 沙格列汀;胰岛素;2型糖尿病;治疗;作用
[中图分类号] R9 [文献标识码] A [文章编号] 1672-4062(2019)02(b)-0082-02
The Role of Saxagliptin Combined with Insulin in the Treatment of Type 2 Diabetes
HU Kai-yan
Zhutian Town Health Center， Feixian County， Linyi， Shandong Province， 273400 China
[Abstract] Objective To investigate the role of saxagliptin in combination with insulin in the treatment of type 2 diabetes. Methods A total of 92 patients with type 2 diabetes mellitus who were treated in our hospital from January 2017 to May 2018 were enrolled in the study. According to the principle of clinical prospective research， the randomized method by using coins was used to divide the disease into two groups， 46 cases each. The control group was given subcutaneous injection of insulin， and the observation group was given saxagliptin combined with insulin treatment， and the therapeutic effects of the two groups were compared. Results There was no significant difference in FPG， 2 hPG and HbAlc between the two groups before treatment (P>0.05). After treatment， the FPG， 2 hPG and HbAlc were significantly lower in the two groups， and the observation group was lower than the control group. The difference between the two groups was significant (P<0.05). Conclusion The combination of saxagliptin and insulin in the treatment of type 2 diabetes is effective and worthy of promotion and use in clinical practice.
[Key words] Saxagliptin; Insulin; Type 2 diabetes; Treatment; Role
糖尿病是一種临床常见的代谢性疾病，其基本特征为高血糖，根据病症特点，可分为I型糖尿病和2型糖尿病这两种症型，其中90.0%患者都属于2型糖尿病，由胰岛素生物作用受损致病，在临床上表现为过度肥胖、疲乏无力等症状[1-2]。作为一种慢性进展性疾病，糖尿病会使得患者长期血糖偏高，并发酮症酸中毒、高渗性高血糖状态、心脑血管疾病、糖尿病肾病、糖尿病周围神经病变等症状，导致患者残疾甚至危及患者性命，必须及时予以治疗。此次试验在2型糖尿病治疗中应用了沙格列汀联合胰岛素用药方案，反响甚好，现报道如下。
1 资料与方法
1.1 一般资料
将在该院治疗的2型糖尿病患者92例作为研究对象，根据临床前瞻性研究原则，采用掷币随机法，将之分为两组，各46例。患者基本资料为：①对照组。男性26例，女性20例，年龄最小者45岁，最大者76岁，平均年龄为(60.15±4.28)岁;病程最短为10个月，最长为9年，平均病程为(4.81±1.26)年;②观察组。男性27例，女性19例，年龄最小者46岁，最大者77岁，平均年龄为(60.53±4.12)岁;病程最短为11个月，最长为9年，平均病程为(4.75±1.30)年。从性别及年龄分布、病程等基本资料上看，对照组和观察组差异无统计学意义(P>0.05)，可进行对比研究。, http://www.100md.com(胡开艳)